Companies/Integrated BioPharma, Inc.

Company profile

Integrated BioPharma, Inc.

OTC: INBP · Healthcare · Medical - Pharmaceuticals

PublicHQ Hillside, NJCIK 0001016504Reports USD

#417 of 1,394 Healthcare companies by revenue53rd-percentile growth

EA Score

67B

FH 71DQ 66GM 58SS 68

v0.1 · 65/100 weight · provisional

↑ listing tenure, return on assets · ↓ Piotroski F, 3-yr revenue growth

Methodology →

Revenue TTM

$48.3M

Rev growth YoY (TTM)

-8.8%

Net income (FY)

$808.0k

Employees

153

Market cap

$5.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$54.4M$54.4M2025

Net income$808.0k$808.0k2025

Operating income$2.0M$2.0M2025

Total assets$24.9M$24.9M2025

Liabilities$4.6M$4.6M2025

Equity$20.3M$20.3M2025

Revenue trend

FY2019 – FY2025 · USD

$43.7M

FY19

$50.0M

FY19

$52.8M

FY20

$63.6M

FY21

$56.2M

FY22

$50.7M

FY23

$50.3M

FY24

$54.4M

FY25

Revenue by segment

Filed disclosures · FY2018

By product

Contract Manufacturing96%

Other Nutraceutical Business3%

Branded Proprietary Products1%

By geography

Europe and Canada100%

The read

Integrated BioPharma, Inc. booked $54.4M in FY2025 revenue, growing 8.0% year over year — about the middle of the pack among Healthcare companies we track, at a 1.5% net margin.

Peers · Healthcare

Silo Pharma, Inc.39D HealthWarehouse.com, Inc.——AIxCrypto Holdings, Inc.36D PD-Rx Pharmaceuticals, Inc.70B

Key facts

CEORiva Sheppard

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersHillside, NJ

ExchangeOTC: INBP

Employees153

IPO date1996-10-30

Latest filings

8-K2026-07-02 10-Q2026-05-08 8-K2026-05-08 8-K2026-04-15 8-K2026-02-18 10-Q2026-02-11 8-K2026-02-11 8-K2025-12-01

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.